August, 2025
August 2025
M T W T F S S
 123
45678910
11121314151617
18192021222324
25262728293031
Hung Trinh: In Vivo Success, Enhanced mRNA Delivery via Cyclic Disulfide-Containing LNPs
Aug 7, 2025, 10:13

Hung Trinh: In Vivo Success, Enhanced mRNA Delivery via Cyclic Disulfide-Containing LNPs

Hung Trinh, Senior VP of Operations at Seneca Therapeutics, shared a post on LinkedIn:

“In vivo demonstration of enhanced mRNA delivery by cyclic disulfide-containing lipid nanoparticles for facilitating endosomal escape

Current LNP technology faces challenges that must be addressed to enhance the functionality of mRNA therapeutics. Recent studies show disulfide-conjugated molecules improve cell membrane permeability. Here, we investigated incorporating cyclic disulfide (CDL) units into lipid components of LNPs to enhance LNP-mRNA performance.

A lipid library with branched and unbranched alkyl chains (C16–C20) and tertiary amine groups modified with CDLs was designed. While cellular uptake was unchanged, some mRNA-loaded LNPs with CDLs achieved more than 2-fold higher transfection efficiency than LNPs with MC3 or SM102 alone. Intracellular analysis revealed that the addition of CDL lipids significantly promoted endosomal escape. The CDL-incorporated LNPs administered subcutaneously in mice showed significantly higher luciferase gene expression compared to LNPs without CDL.

Additionally, LNPs encapsulating OVA antigen-encoding mRNA induced a potent antitumor response against the EG7-OVA lymphoma model. These results suggest CDL modifications enhance LNP-based mRNA delivery, offering potential for broader therapeutic applications and improved clinical outcomes.”

Title: In vivo demonstration of enhanced mRNA delivery by cyclic disulfide-containing lipid nanoparticles for facilitating endosomal escape

Authors: Seigo Kimura, Kana Okada, Noriaki Matsubara, Fangjie Lyu, Susumu Tsutsumi, Yasuaki Kimura, Fumitaka Hashiya, Masahito Inagaki, Naoko Abe, Hiroshi Abe

Read Full Article.

Hung Trinh

More posts featuring Hung Trinh on OncoDaily.